ATRI — Atrion Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedMid CapNeutral
- $534.99m
- $534.99m
- $183.51m
- 88
- 46
- 34
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.23 | ||
| Price to Tang. Book | 2.33 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.17 | ||
| EV to EBITDA | 13.62 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.91% | ||
| Return on Equity | 8.76% | ||
| Operating Margin | 14.66% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 152.45 | 155.07 | 147.59 | 165.01 | 183.51 | n/a | n/a | 4.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +3.28 | +6.98 | -11.56 | +4.23 | +7.56 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Atrion Corporation (Atrion) is engaged in the development and manufacture of products for medical applications. The Company's medical products primarily serve the fluid delivery, cardiovascular and ophthalmology markets. It has developed a variety of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in fields, such as anesthesia and oncology. Atrion's cardiovascular product, Myocardial Protection System (MPS3), is a technology used in open-heart surgery that delivers fluids and medications, mixes critical drugs, and controls temperature and pressure. Its ophthalmic products include specialized medical devices that disinfect contact lenses. Atrion also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. Its medical and non-medical products are manufactured at facilities in Florida, Alabama and Texas.
Directors
- Emile Battat CHM (83)
- David Battat CEO (51)
- Jeffery Strickland CFO (62)
- Ronald Spaulding LED (57)
- Preston Athey IND (71)
- Hugh Morgan IND (92)
- Maria Sainz IND (55)
- John Stupp IND (71)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 30th, 1996
- Public Since
- March 18th, 1980
- No. of Shareholders
- 14,739
- No. of Employees
- 722
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 1,759,836
- Address
- One Allentown Parkway, ALLEN, 75002
- Web
- https://atrioncorp.com/
- Phone
- +1 9723909800
- Auditors
- Grant Thornton LLP
Upcoming Events for ATRI
Q4 2023 Atrion Corp Earnings Release
Q1 2024 Atrion Corp Earnings Release
Atrion Corp Annual Shareholders Meeting
Similar to ATRI
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Atrion share price?
As of Today at 18:03 UTC, shares in Atrion are trading at $304.00. This share price information is delayed by 15 minutes.
How has the Atrion share price performed this year?
Shares in Atrion last closed at $304.00 and the price had moved by -49.17% over the past 365 days. In terms of relative price strength the Atrion share price has underperformed the S&P500 Index by -55.11% over the past year.
What are the analyst and broker recommendations for Atrion?
The overall consensus recommendation for Atrion is Sell. You can view the full broker recommendation list by unlocking its StockReport.
What is the Atrion dividend yield?
The Atrion dividend yield is 2.85% based on the trailing twelve month period.
Does Atrion pay a dividend?
Last year, Atrion paid a total dividend of $8.65, and it currently has a trailing dividend yield of 2.85%.Looking ahead, shares in Atrion are due to go ex-dividend on 2023-11-30 and the next dividend pay date is 2023-12-15.
When does Atrion next pay dividends?
Atrion are due to go ex-dividend on 2023-11-30 and the next dividend pay date is 2023-12-15. The historic dividend yield on Atrion shares is currently 2.85%.
How do I buy Atrion shares?
To buy shares in Atrion you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Atrion?
As of the previous close price of $304.00, shares in Atrion had a market capitalisation of $534.99m.
Where are Atrion shares listed?
Here are the trading details for Atrion:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ATRI
What kind of share is Atrion?
Based on an overall assessment of its quality, value and momentum Atrion is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Atrion share price forecast for 2023?
We could not find analyst target price data for this security.
What is the trend in the Atrion share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atrion. Over the past six months, its share price has underperformed the S&P500 Index by -45.91%.
As of the last closing price of $304.00, shares in Atrion were trading -41.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Atrion PE Ratio?
The Atrion PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $304.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Atrion?
Atrion's management team is headed by:
- Emile Battat - CHM
- David Battat - CEO
- Jeffery Strickland - CFO
- Ronald Spaulding - LED
- Preston Athey - IND
- Hugh Morgan - IND
- Maria Sainz - IND
- John Stupp - IND